000170227 001__ 170227 000170227 005__ 20260407115449.0 000170227 0247_ $$2doi$$a10.1016/j.ejcskn.2026.100781 000170227 0248_ $$2sideral$$a148762 000170227 037__ $$aART-2026-148762 000170227 041__ $$aeng 000170227 100__ $$aAguado, Leyre 000170227 245__ $$aTirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 202 000170227 260__ $$c2026 000170227 5060_ $$aAccess copy available to the general public$$fUnrestricted 000170227 5203_ $$aPurpose. This article provides an overview of the scientific content on tirbanibulin 1 % ointment, summarizing key Phase IV results and real-life experiences with tirbanibulin shared by dermatologists across Europe. Materials and Methods. Summary of posters, oral presentation and symposium discussions related to tirbanibulin presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato Oncology (EADO) Congress held between 3rd and 5th of April 2025 in Athens, Greece. Results. We report presented data on the efficacy/effectiveness, safety and tolerability of tirbanibulin 1 % ointment for the treatment of actinic keratosis (AK) on the face, scalp and décolleté. We also collected evidence supporting its use in AK in organ transplant recipients (OTR), solar damaged skin, pigmented AK (PAK), proliferative AK, hypertrophic AK, actinic cheilitis (AC), keratinocyte carcinoma (KC) and lentigo maligna (LM). Conclusions. Overall, data from a Phase IV trial and real-world clinical practice suggest that tirbanibulin is an effective, safe and well-tolerated treatment for AK. Tirbanibulin may also be an option for OTR, patients with PAK, proliferative or hypertrophic AK, and even for conditions such as AC or KC, although the sample size is small in some of these groups and further evidence is needed. 000170227 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es 000170227 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000170227 700__ $$aBorgia, Francesco 000170227 700__ $$aBroganelli, Paolo 000170227 700__ $$aCoronel Pérez, Isabel María 000170227 700__ $$aDirschka, Thomas Peter 000170227 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza 000170227 700__ $$aGualdi, Giulio 000170227 700__ $$aHobelsberger, Sarah 000170227 700__ $$aLuque Varela, Pilar 000170227 700__ $$aMoyano, Blanca 000170227 700__ $$aPatel, Girish K. 000170227 700__ $$aPuig, Susana 000170227 700__ $$aSavoia, Paola 000170227 700__ $$aZalaudek, Iris 000170227 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000170227 773__ $$g4 (2026), 6 pp.$$pEJC skin cancer$$tEJC skin cancer$$x2772-6118 000170227 8564_ $$s3149629$$uhttps://zaguan.unizar.es/record/170227/files/texto_completo.pdf$$yVersión publicada 000170227 8564_ $$s2101301$$uhttps://zaguan.unizar.es/record/170227/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000170227 909CO $$ooai:zaguan.unizar.es:170227$$particulos$$pdriver 000170227 951__ $$a2026-03-26-14:32:06 000170227 980__ $$aARTICLE